Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GS-9911 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part A: GS-9911 Monotherapy Dose Escalation | EXPERIMENTAL | Participants will receive escalating doses of GS-9911 monotherapy. |
| Part B: GS-9911 Monotherapy Dose Expansion | EXPERIMENTAL | Participants will receive GS-9911 monotherapy at the recommended dose for expansion (RDE) determined in Part A. |
| Part C: Dose Escalation: GS-9911 + Anti-PD-1 Monoclonal Antibody | EXPERIMENTAL | Participants will receive escalating doses of GS-9911 in combination with an anti-PD-1 monoclonal antibody (zimberelimab). |
| Part D: Dose Expansion: GS-9911 + Anti-PD-1 Monoclonal Antibody | EXPERIMENTAL | Participants will receive GS-9911 at RDE determined in Part C in combination with an anti-PD-1 monoclonal antibody (zimberelimab). |
| Name | Type | Description |
|---|---|---|
| GS-9911 | DRUG | Tablets administered orally |
| Zimberelimab | DRUG | Administered intravenously |
Key Inclusion Criteria: * Parts A, C, and D: * Participants with histologically or cytologically confirmed advanced solid tumors who have received, been intolerant to, or are ineligible for all treatments known to confer clinical benefit * Part B: * Participants whose cancer previously derive...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
GS-9911 is an investigational small molecule being developed for the treatment of solid tumors. It is currently in Phase 1 clinical development, with an active trial studying its use alone or in combination with an antibody treatment in adults with solid tumors.
GS-9911 is being developed by Gilead Sciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol GILD. The company is conducting a Phase 1 clinical trial to evaluate the drug in patients with solid tumors.
GS-9911 is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities, and is being studied in an active clinical trial for the treatment of solid tumors in adults.
GS-9911 is being studied in a Phase 1 clinical trial with the identifier NCT06082960. This trial is titled 'Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors' and is currently active but not recruiting participants.
No alternative names for GS-9911 have been disclosed. The drug is identified by its code name GS-9911 in clinical trial registrations and is being developed by Gilead Sciences for the treatment of solid tumors.